Newly discovered genetic variations may help predict breast cancer risk in women who receive preventive breast cancer therapy with the selective estrogen receptor modulator drugs tamoxifen and raloxifene, a Mayo Clinic-led study has found. Mayo Clinic oncologist, James Ingle, M.D., says, “Our findings are important, because we identified genetic factors that could eventually be used to select women who should be offered the drugs for prevention.”